Drug Profile
Research programme: cancer therapeutics - VLife Sciences Technologies
Alternative Names: VB 473Latest Information Update: 02 Feb 2011
Price :
$50
*
At a glance
- Originator VLife Sciences Technologies
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 31 Dec 2006 Discontinued - Preclinical for Cancer in India (unspecified route)
- 30 Nov 2005 Preclinical trials in Cancer in India (unspecified route)